sucujovide.wordpress.com
Hematide is in a Phase III trial. Rentoh led Onyx for nearly 15 years, stepping down in Februart 2008as president, CEO, chairman and a membe of Onyx’s board. At the company, he helpe d negotiate a research, development and commercialization partnershi with that resulted inthe anti-cancer drug Nexavar tablets, which cost about $5,000 a month in the Unites States and are approaching $1 billion in annual sales, are approved in more than 80 countries to treag kidney cancer and 70-pluas countries for liver cancer. Prior to joining Renton was president and COOof Chiron, whichu acquired Cetus in 1991. Renton had been presidenrt of Cetussince 1990, COO since 1987 and CFO from 1983 to 1987.
Renton also serves on the boardswof , Cepheid and the Special Olympics of Northermn California.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment